The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.smaller Cos. Regulatory News (BSV)

Share Price Information for Br.smaller Cos. (BSV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 80.00
Bid: 78.50
Ask: 81.50
Change: 0.00 (0.00%)
Spread: 3.00 (3.822%)
Open: 80.00
High: 81.50
Low: 80.00
Prev. Close: 80.00
BSV Live PriceLast checked at -
British Smaller Companies VCT is an Investment Trust

To maximise Total Return and provide investors with an attractive long-term tax-free dividend yield while maintaining the Company's status as a venture capital trust.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

3rd Quarter Results

15 Mar 2024 12:15

RNS Number : 0800H
British Smaller Companies VCT PLC
15 March 2024
 

British Smaller Companies VCT plc

Interim Management Statement

For the quarter ended 31 December 2023

British Smaller Companies VCT plc (the "Company") presents its interim management statement for the quarter ended 31 December 2023. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

In the quarter to 31 December 2023, the Company's Net Asset Value per share was up by 3.3 pence, or 4.0 per cent of the opening NAV, prior to the payment of the interim dividend of 2.0 pence on 8 December 2023. The FTSE Small Cap Index rose by 5.4 per cent during the period.

The Company's Total Return at 31 December 2023 was up 3.3 pence, to 262.6 pence per ordinary share.

During the quarter, the Company invested a further £0.8 million into Force24 and £0.5 million into Vuealta. Subsequent to the quarter end, the Company has invested £1.8 million into three follow on investments; Outpost, Relative Insight and SharpCloud.

In November 2023 the Company exited its investment in E2E for £2.0 million, representing a 2.5x return on the Company's cost. Also in November, the investment in MacroArt was realised for £1.5 million, representing a 2.0x return on cost for the Company. 

The Company has seen further realisations post-quarter-end, partially realising its investments in KeTech and Arcus in January 2024, and fully exiting its investment in Displayplan in February 2024, all at valuations in line with fair value at 31 December 2023.

To maximise shareholder value, the KeTech business was split into its two component parts, Rail and Defence. The Defence business subsequently sold in January 2024, generating proceeds of £1.5 million. To date, the Company has realised proceeds of £4.1 million from its KeTech investment, a 2.0x return on cost, while still retaining its investment in the Rail Business, which at the period end was valued at £1.3 million.

In February 2024, the Company sold its investment in Displayplan for £9.0 million. Total proceeds received over the life of the investment are £12.5 million, an excellent 9.6x return on the Company's cost. There is the potential for further deferred proceeds in due course. 

Performance

The table below sets out movements in key metrics for the Company. 

 

 

30 September 2023

Increase in Value

Shares issued/dividend paid

Buyback of shares

Movement

In Period

31 December 2023

Net Assets (£m)

198.6

7.8

(3.8)

(0.8)

3.2

201.8

NAV per share (PPS)

82.4

3.3

(2.0)

-

1.3

83.7

Cumulative dividends paid (PPS)

176.9

-

2.0

-

2.0

178.9

Total Return (PPS)

259.3

3.3

-

-

3.3

262.6

Shares in issue

240,991,484

-

1,220,008

(975,567)

244,441

241,235,925

Cumulative dividends paid at 31 December 2023 were 178.9 pence per ordinary share (30 September 2023: 176.9 pence per ordinary share) following the interim dividend of 2.0 pence paid on 8 December 2023.

The movements in NAV and NAV per ordinary share are set out in the table below:

 

 

£m

Pence per

ordinary share

NAV at 30 September 2023

198.6

82.4

Increase in portfolio value

7.6

3.2

Net operating income

0.2

0.1

7.8

3.3

Issue/buy-back of shares

0.2

-

Total Return in the period

8.0

3.3

NAV before dividends

206.6

85.7

Dividends paid

(4.8)

(2.0)

NAV at 31 December 2023

 

201.8

 

83.7

 

Dividends and shares in issue

On 8 December 2023 the Company issued 1,220,008 shares under the Company's Dividend Re-investment Scheme (DRIS).

Under its standing buyback authority, on 18 December 2023 the Company purchased 975,567 shares at 76.88 pence per share at a cost of £0.8 million. These shares are held in treasury. 

On 30 January 2024 the Company issued 22,560,594 shares in relation to its 2023/24 fundraising, following which the Company's issued share capital consists of 263,796,519 ordinary shares with voting rights and 24,501,263 shares held in treasury.

Net assets

Net assets at 31 December 2023 comprised the following:

£000

% of net assets

Unquoted investments at fair value

135,649

67.2

Cash and money market funds

63,490

31.5

Other net assets

2,655

1.3

Net assets

201,794

100.0

Investments

The investment portfolio at 31 December 2023 comprised:

Valuation

£000

Cumulative valuation as a % of net assets

Matillion

26,440

13.1%

Unbiased

12,545

19.3%

Outpost

8,819

23.7%

Displayplan

8,806

28.1%

Elucidat

6,596

31.3%

Force24

6,189

34.4%

Wooshii

5,457

37.1%

SharpCloud

4,965

39.6%

Vypr

4,834

41.9%

ACC Aviation

4,340

44.1%

88,991

44.1%

Other investments

46,658

67.2%

Total investments

135,649

67.2%

Portfolio performance

Over the quarter to 31 December 2023, the aggregate unquoted portfolio valuation has increased by £7.6 million.

Fundraising

The Company announced a new share offer on 20 September 2023, alongside British Smaller Companies VCT2 plc, with the intention of raising up to £90 million, in aggregate, which included an over-allotment facility of £25 million, in aggregate. The offers closed to new Applications on 16 February 2024. Gross Applications of £90 million have been received, of which c.£55.5 million relate to the Company. The first allotment of £30 million (£18.6 million relating to the Company) took place on 30 January 2024; the second and final allotment will take place in early April 2024.

Outlook

In the last quarter of the year, there was a notable upturn in the economic forecast. We witnessed a decline in inflation rates and a growing consensus that interest rates might be lowered in 2024. Nevertheless, we're keeping a close eye on any potential shifts, particularly given recent instability in the Middle East, which have raised concerns about a resurgence in input costs. Additionally, upcoming elections in both the UK and US in 2024 may influence the economic outlook.

The portfolio has demonstrated robust revenue growth in an efficient manner through a tough trading period, which should leave portfolio companies well positioned to continue their positive trajectory as the economic environment improves. Moreover, the close of the Company's 2023/24 fundraising in February positions the Company strongly to continue supporting the portfolio and to invest further in new opportunities in the year ahead.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

15 March 2024

For further information please contact:

David Hall YFM Private Equity Limited Tel: 0113 244 1000

Alex Collins Panmure Gordon (UK) Limited Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTEAFDSFSKLEFA
Date   Source Headline
3rd Apr 20247:58 amRNSIssue of Equity and Close of Offers
26th Mar 202411:11 amRNSTransaction in Own Shares and Total Voting Rights
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNS3rd Quarter Results
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:23 amRNSIssue of Equity
18th Dec 20234:02 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
8th Dec 20239:47 amRNSPayment of Dividend and Issue of Equity
24th Nov 20237:00 amRNSHalf-year Report
26th Oct 20231:34 pmRNSDividend Declaration
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:20 amRNSTransaction in Own Shares and PDMR
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
14th Sep 202310:28 amRNSResult of AGM
14th Sep 202310:28 amRNSResult of General Meeting
13th Sep 20237:00 amRNS1st Quarter Results
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
28th Jul 202310:00 amRNSDirector/PDMR Shareholding
28th Jul 202310:00 amRNSPayment of Dividend and Issue of Equity
27th Jun 20237:45 amRNSTransaction in Own Shares
21st Jun 20231:00 pmRNSPublication of Circular
16th Jun 202312:00 pmRNSAnnual Financial Report
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:23 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:42 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNS3rd Quarter Results
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSDirector/PDMR Shareholding
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:48 amRNSTransaction in Own Shares
6th Dec 20229:58 amRNSOffer Update
6th Dec 20229:58 amRNSOffer Update
30th Nov 202212:30 pmRNSPublication of a Prospectus
30th Nov 202212:30 pmRNSPublication of a Prospectus
25th Nov 20229:30 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.